JP2022519675A5 - - Google Patents
Info
- Publication number
- JP2022519675A5 JP2022519675A5 JP2021545958A JP2021545958A JP2022519675A5 JP 2022519675 A5 JP2022519675 A5 JP 2022519675A5 JP 2021545958 A JP2021545958 A JP 2021545958A JP 2021545958 A JP2021545958 A JP 2021545958A JP 2022519675 A5 JP2022519675 A5 JP 2022519675A5
- Authority
- JP
- Japan
- Prior art keywords
- grade
- use according
- topical composition
- composition
- severity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962804235P | 2019-02-12 | 2019-02-12 | |
| US62/804,235 | 2019-02-12 | ||
| PCT/IB2020/051073 WO2020165755A1 (en) | 2019-02-12 | 2020-02-11 | Use of topical braf inhibitor compositions for treatment of radiation dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519675A JP2022519675A (ja) | 2022-03-24 |
| JP2022519675A5 true JP2022519675A5 (OSRAM) | 2023-01-05 |
Family
ID=72044789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545958A Pending JP2022519675A (ja) | 2019-02-12 | 2020-02-11 | 放射線皮膚炎の治療のための局所用ｂｒａｆ阻害剤組成物の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11439648B2 (OSRAM) |
| EP (1) | EP3923911B1 (OSRAM) |
| JP (1) | JP2022519675A (OSRAM) |
| KR (1) | KR102534457B1 (OSRAM) |
| CN (1) | CN113382717A (OSRAM) |
| AU (1) | AU2020220895B9 (OSRAM) |
| BR (1) | BR112021015137A2 (OSRAM) |
| CA (1) | CA3127175C (OSRAM) |
| ES (1) | ES2952251T3 (OSRAM) |
| HR (1) | HRP20231241T1 (OSRAM) |
| HU (1) | HUE063091T2 (OSRAM) |
| IL (1) | IL285560B2 (OSRAM) |
| MX (1) | MX2021009535A (OSRAM) |
| PL (1) | PL3923911T3 (OSRAM) |
| RS (1) | RS64618B1 (OSRAM) |
| WO (1) | WO2020165755A1 (OSRAM) |
| ZA (1) | ZA202106581B (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3203021A1 (en) * | 2020-12-24 | 2022-06-30 | Noa Shelach | Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions |
| MX2024000227A (es) * | 2021-07-02 | 2024-04-16 | Lutris Pharma Ltd | Uso de isoquinolina-1,5-diaminas para la curacion de heridas. |
| CN118139621A (zh) * | 2021-09-30 | 2024-06-04 | 北京大学 | 一种对红系前体细胞或成红细胞进行扩增的方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| WO2008153947A2 (en) | 2007-06-07 | 2008-12-18 | Amgen Inc. | Heterocyclic compounds as raf kinase modulators |
| PL2947072T3 (pl) * | 2008-03-17 | 2017-05-31 | Ambit Biosciences Corporation | 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych |
| WO2011117381A1 (en) * | 2010-03-26 | 2011-09-29 | Boehringer Ingelheim International Gmbh | B-raf kinase inhibitors |
| US20130226549A1 (en) | 2012-02-27 | 2013-08-29 | Yufeng J. Tseng | Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| JP2017514866A (ja) * | 2014-05-06 | 2017-06-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｂｒａｆ阻害剤を使用する創傷治癒 |
| ES2947237T3 (es) * | 2016-03-10 | 2023-08-03 | Lutris Pharma Ltd | Uso de inhibidores de BRaf para el tratamiento de reacciones cutáneas |
| WO2019026065A2 (en) * | 2017-07-29 | 2019-02-07 | Lutris Pharma Ltd. | NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS |
| WO2019032717A1 (en) * | 2017-08-08 | 2019-02-14 | Memorial Sloan Kettering Cancer Center | USE OF BRAF INHIBITORS FOR TREATING SKIN REACTIONS CAUSED BY TREATMENT WITH MEK INHIBITOR |
-
2020
- 2020-02-11 IL IL285560A patent/IL285560B2/en unknown
- 2020-02-11 AU AU2020220895A patent/AU2020220895B9/en active Active
- 2020-02-11 WO PCT/IB2020/051073 patent/WO2020165755A1/en not_active Ceased
- 2020-02-11 MX MX2021009535A patent/MX2021009535A/es unknown
- 2020-02-11 CA CA3127175A patent/CA3127175C/en active Active
- 2020-02-11 JP JP2021545958A patent/JP2022519675A/ja active Pending
- 2020-02-11 PL PL20756229.9T patent/PL3923911T3/pl unknown
- 2020-02-11 ES ES20756229T patent/ES2952251T3/es active Active
- 2020-02-11 EP EP20756229.9A patent/EP3923911B1/en active Active
- 2020-02-11 RS RS20230855A patent/RS64618B1/sr unknown
- 2020-02-11 KR KR1020217029012A patent/KR102534457B1/ko active Active
- 2020-02-11 CN CN202080012207.4A patent/CN113382717A/zh active Pending
- 2020-02-11 HU HUE20756229A patent/HUE063091T2/hu unknown
- 2020-02-11 HR HRP20231241TT patent/HRP20231241T1/hr unknown
- 2020-02-11 BR BR112021015137-0A patent/BR112021015137A2/pt unknown
-
2021
- 2021-07-23 US US17/384,221 patent/US11439648B2/en active Active
- 2021-09-07 ZA ZA2021/06581A patent/ZA202106581B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2745415C (en) | Methods for preventing or reducing carcinogenesis or oxidative stress | |
| JP2019189650A5 (OSRAM) | ||
| RU2644635C2 (ru) | Системы, способы и составы для лечения рака | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| JP2022188083A5 (OSRAM) | ||
| ES2911110T3 (es) | Combinaciones de tofacitinib y crisaborol para uso en el tratamiento de enfermedades inflamatorias de la piel | |
| JP2009534306A5 (OSRAM) | ||
| JP2017528505A5 (OSRAM) | ||
| CN101972225A (zh) | 一种含吡非尼酮的凝胶组合物 | |
| RU2013100383A (ru) | Композиции полиэтиленгликоля для контроля рецидивов лабиального герпеса, генитального герпеса и опоясывающего герпеса | |
| HRP20231241T1 (hr) | Upotreba sastava braf inhibitora za lokalnu primjenu za liječenje radijacijskog dermatitisa | |
| JP2012525358A5 (OSRAM) | ||
| AU780844B2 (en) | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | |
| JP2015081244A (ja) | ニキビ治療用医薬組成物 | |
| JP2010504969A (ja) | Ｓａｈａのアミン塩基塩及びその多形 | |
| EP3592351A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| RU2021126784A (ru) | Применение композиций на основе ингибитора braf для наружнего применения для лечения лучевого дерматита | |
| CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| JP2017530132A5 (OSRAM) | ||
| JP2023502251A (ja) | ファルネソイドｘ受容体（ｆｘｒ）を介した転写応答を誘導または促進する方法 | |
| RU2812708C2 (ru) | Применение композиций на основе ингибитора braf для наружного применения для лечения лучевого дерматита | |
| WO2017096025A1 (en) | Norpregnane derivatives for the risk reduction of breast cancer | |
| Wang et al. | 657 TGF-β2 upregulates OPN3 in human epidermal melanocytes independent of TGF-β2R in vitro | |
| Gibson et al. | 660 Dual HDAC and LSD1 inhibition as a novel strategy to overcome BRAF inhibitor resistance | |
| JPS60146823A (ja) | 消炎鎮痛性外用医薬組成物 |